Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy

被引：11

作者：

An, Xin ^{[1
,2
]}

Ding, Pei-Rong ^{[1
,3
]}

Xiang, Xiao-Juan ^{[1
,2
]}

Wang, Zhi-Qiang ^{[1
,2
]}

Wang, Feng-Hua ^{[1
,2
]}

Feng, Fen ^{[1
,2
]}

Jiang, Wen-Qi ^{[1
,2
]}

He, You-Jian ^{[1
,2
]}

Xu, Rui-Hua ^{[1
]}

Li, Yu-Hong ^{[1
,2
]}

机构：

[1] State Key Lab Oncol S China, Guangzhou, Guangdong, Peoples R China

[2] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China

[3] Sun Yat Sen Univ, Ctr Canc, Dept Colorectal Surg, Guangzhou, Guangdong, Peoples R China

来源：

BIOMARKERS | 2010年 / 15卷 / 03期

关键词：

Carcinoembryonic antigen surge; chemotherapy; irinotecan; metastatic colorectal cancer; FOLINIC ACID; COLON-CANCER; TUMOR-MARKER; CEA; EXPRESSION; 5-FLUOROURACIL; OXALIPLATIN; THERAPY; CELLS; INCREASE;

D O I：

10.3109/13547500903477377

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Methods: We retrospectively reviewed 132 patients with metastatic colorectal cancer treated with irinotecan-based chemotherapy. Incidence of a CEA surge and chemotherapy efficacy were investigated. Results: Eleven of 99 eligible patients (11.1%) had CEA surges. None of the 11 patients showed progressive disease (four had a partial response, seven had stable disease). Conclusion: A CEA surge can be induced by irinotecan-based chemotherapy. An early increase in CEA after irinotecan-based chemotherapy does not usually indicate progression of disease and failure of therapy, and should not lead to a change of chemotherapy.

引用

页码：243 / 248

页数：6

共 50 条

[41] Salvage chemotherapy in metastatic colorectal cancer with the combination of capecitabine and mitomycin C [J].

Zygulska, A. L. ;

Krzemieniecki, K. .

NEOPLASMA, 2015, 62 (05) :793-797

[42] Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial [J].

Cheng, Ke ;

Zhou, Yu-Wen ;

Chen, Ye ;

Li, Zhi-Ping ;

Qiu, Meng ;

Liu, Ji-Yan .

CANCER CONTROL, 2022, 29

[43] ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer [J].

Trumpi, K. ;

Emmink, B. L. ;

Prins, A. M. ;

van Oijen, M. G. H. ;

van Diest, P. J. ;

Punt, C. J. A. ;

Koopman, M. ;

Kranenburg, O. ;

Rinkes, I. H. M. Borel .

JOURNAL OF CANCER, 2015, 6 (11) :1079-1086

[44] Irinotecan-Cetuximab-Bevacizumab as a Salvage Treatment in Heavily Pretreated Metastatic Colorectal Cancer Patients: A Retrospective Observational Study [J].

Feliu Batlle, J. ;

Cuadrado, E. ;

Castro, J. ;

Caldes, T. ;

Belda, C. ;

Sastre, J. ;

Barriuso, J. ;

Martinez Marin, V. ;

Diaz-Rubio, E. ;

Gonzalez-Baron, M. .

CHEMOTHERAPY, 2011, 57 (02) :138-144

[45] Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients [J].

Labriet, Adrien ;

Levesque, Eric ;

De Mattia, Elena ;

Cecchin, Erika ;

Jonker, Derek ;

Couture, Felix ;

Simonyan, David ;

Buonadonna, Angela ;

D'Andrea, Mario ;

Villeneuve, Lyne ;

Toffoli, Giuseppe ;

Guillemette, Chantal .

PHARMACOGENOMICS, 2019, 20 (17) :1179-1187

[46] Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progressionfree survival in patients with advanced and/or metastatic colorectal cancer [J].

Wulaningsih, Wahyu ;

Wardhana, Ardyan ;

Watkins, Johnathan ;

Yoshuantari, Naomi ;

Repana, Dimitra ;

Van Hemelrijck, Mieke .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (02)

[47] Carcinoembryonic antigen expression level as a predictive factor for response to 5-fluorouracil in colorectal cancer [J].

Eftekhar, Ebrahim ;

Naghibalhossaini, Fakhraddin .

MOLECULAR BIOLOGY REPORTS, 2014, 41 (01) :459-466

[48] Combination of irinotecan and other drugs in the treatment of colorectal metastatic cancer [J].

Ducreux, M ;

Gil-Delgado, M ;

André, T ;

Ychou, M ;

de Gramond, A ;

Khayat, D .

BULLETIN DU CANCER, 1998, :43-46

[49] Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer [J].

P García-Alfonso ;

A J Muñoz-Martin ;

S Alvarez-Suarez ;

Y Jerez-Gilarranz ;

M Riesco-Martinez ;

P Khosravi ;

M Martin .

British Journal of Cancer, 2010, 103 :1524-1528

[50] A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon [J].

Temraz, Sally ;

Nasr, Fadi ;

Kattan, Joseph ;

Abigerges, Dany ;

Moukadem, Walid ;

Farhat, Fadi ;

Maatouk, Layal ;

Chahine, Georges ;

Shamseddine, Ali .

BIOLOGICS-TARGETS & THERAPY, 2022, 16 :7-15

← 1 2 3 4 5 →